Compare Amphastar Pharmaceuticals Inc (AMPH) vs Global X Uranium ETF (URA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

URA (Global X Uranium ETF) trades at $42.97, up 1.46% today but showing a bearish technical trend with 13 sell signals in moving averages. The fund holds $6.29 billion in assets across 56 uranium and nuclear energy companies. Recent news highlights strong thematic tailwinds from AI-driven power demand and government support for nuclear energy, positioning URA at the intersection of energy security and technology infrastructure growth.

The outlook for URA is supported by structural demand drivers but faces near-term technical weakness. Investment opportunity lies in the nuclear renaissance narrative, while risks include ETF liquidity constraints and uranium price volatility. The fund's 0.52% expense ratio is higher than broad energy ETFs, requiring sustained thematic performance to justify costs.